Genetic heterogeneity in adult dominant polycystic kidney disease in Cypriot families

• Published in: Human genetics Vol. 95; no. 4; p. 416
• Main Authors: Constantinou-Deltas, C D, Papageorgiou, E, Boteva, K, Christodoulou, K, Breuning, M H, Peter, D J, Pierides, A
• Format: Journal Article
• Language: English
• Published: Germany 01.04.1995
• Subjects: Aged; Cyprus - epidemiology; DNA - analysis; DNA Probes; Female; Gene Frequency; Genetic Heterogeneity; Genetic Linkage; Genetic Markers; Humans; Male; Middle Aged; Pedigree; Phenotype; Polycystic Kidney, Autosomal Dominant - diagnosis; Polycystic Kidney, Autosomal Dominant - epidemiology; Polycystic Kidney, Autosomal Dominant - genetics; Cyprus
• ISSN: 0340-6717
• DOI: 10.1007/BF00208967

Polycystic kidney disease is an inherited heterogeneous disorder that affects approximately 1:1000 Europeans. It is characterized mainly by the formation of cysts in the kidney that lead to end-stage renal failure with late age of onset. Three loci have been identified, PKD1 on the short arm of chromosome 16, which has recently been isolated and characterized, PKD2 on the long arm of chromosome 4, and a third locus of unknown location, that is apparently much rarer. In families that transmit the PKD2 gene there is a significantly later age of onset of symptoms, compared with families that transmit the PKD1 gene, and in general they present with milder progression of symptomatology. For the first time we attempted molecular genetic analysis in seven Cypriot families using highly polymorphic markers around the PKD1 and PKD2 genes. Our data showed that there is genetic and phenotypic heterogeneity among these families. For four of the families we obtained strong evidence for linkage to the PKD1 locus. In two of these families linkage to PKD1 was strengthened by excluding linkage to PKD2 with the use of marker D4S423. In three other families we showed linkage to the PKD2 locus. In the largest of these families one recombinant placed marker D4S1534 distal to D4S231, thereby rendering it the closest proximal marker known to us to date. The application of molecular methods allowed us to make presymptomatic diagnosis for a number of at-risk individuals.